Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.
Sanchez L, Vesole DH, Richter JR, Biran N, Bilotti E, McBride L, Anand P, Ivanovski K, Siegel DS. Sanchez L, et al. Among authors: richter jr. Br J Haematol. 2017 Feb;176(3):440-447. doi: 10.1111/bjh.14429. Epub 2016 Nov 18. Br J Haematol. 2017. PMID: 27859001 Free article. Clinical Trial.
Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma.
Biran N, Gourna Paleoudis E, Feinman R, Vesole DH, Zenreich J, Wang S, Ahn J, Bansal M, Rowley S, Donato M, Pecora AL, Richter J, Anand P, McBride L, Ivanovski K, Korngold R, Siegel DS. Biran N, et al. Am J Hematol. 2021 Nov 1;96(11):E430-E433. doi: 10.1002/ajh.26333. Epub 2021 Sep 17. Am J Hematol. 2021. PMID: 34435374 Free article. Clinical Trial. No abstract available.
Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Vesole DH, Bilotti E, Richter JR, McNeill A, McBride L, Raucci L, Anand P, Bednarz U, Ivanovski K, Smith J, Batra V, Aleman A, Sims T, Guerrero L, Mato A, Siegel DS. Vesole DH, et al. Among authors: richter jr. Br J Haematol. 2015 Oct;171(1):52-9. doi: 10.1111/bjh.13517. Epub 2015 May 27. Br J Haematol. 2015. PMID: 26018491 Free article. Clinical Trial.
A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma.
Cornell RF, Baz R, Richter JR, Rossi A, Vogl DT, Chen C, Shustik C, Alvarez MJ, Shen Y, Unger TJ, Ben-Shahar O, Wang H, Baloglu E, Senapedis W, Ma X, Landesman Y, Bai X, Bader J, Xu H, Marshall T, Chang H, Walker CJ, Shah J, Shacham S, Kauffman MG, Hofmeister CC. Cornell RF, et al. Among authors: richter jr. Am J Hematol. 2022 Feb 1;97(2):E54-E58. doi: 10.1002/ajh.26420. Epub 2021 Nov 30. Am J Hematol. 2022. PMID: 34817872 Free article. Clinical Trial. No abstract available.
A 3-O-sulfated heparan sulfate dodecasaccharide (12-mer) suppresses thromboinflammation and attenuates early organ injury following trauma and hemorrhagic shock.
Vidaurre MDPH, Osborn BK, Lowak KD, McDonald MM, Wang YW, Pa V, Richter JR, Xu Y, Arnold K, Liu J, Cardenas JC. Vidaurre MDPH, et al. Among authors: richter jr. Front Immunol. 2023 Apr 14;14:1158457. doi: 10.3389/fimmu.2023.1158457. eCollection 2023. Front Immunol. 2023. PMID: 37122735 Free PMC article.
The glycocalyx: Pathobiology and repair.
Richter JR, Sanderson RD. Richter JR, et al. Matrix Biol Plus. 2023 Jan 20;17:100128. doi: 10.1016/j.mbplus.2023.100128. eCollection 2023 Feb. Matrix Biol Plus. 2023. PMID: 36793504 Free PMC article. No abstract available.
68 results